Monoclonal antibody therapies-a 'constant' threat to cancer.
Houghton
A N
AN
Scheinberg
D A
DA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D017452:Receptors, IgG / Q000276:immunology*; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000970:Antineoplastic Agents; C080571:Fc gamma receptor IIB; D017452:Receptors, IgG; D000069283:Rituximab; D000068878:Trastuzumab